Finocchiaro G, Špringer T, Krejčík Z, Bocková M, Merkerová MD, Homola J. Large gold nanoparticle release assay for attomolar detection of miRNA related to myelodysplastic neoplasms.
Talanta 2025;
293:128037. [PMID:
40199123 DOI:
10.1016/j.talanta.2025.128037]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2025] [Revised: 03/21/2025] [Accepted: 03/27/2025] [Indexed: 04/10/2025]
Abstract
MicroRNAs (miRNAs) hold potential as biomarkers for numerous cancer types, including myelodysplastic neoplasms (MDS). Here, we present a highly sensitive assay based on the oligonucleotide-triggered release of gold nanoparticles (AuNPs) for the detection of hsa-miR-451a with a surface plasmon resonance biosensor. The performance of the assay is in large part determined by the size and functional coating of AuNPs. Therefore, we investigate AuNPs in a size range from 43 to 170 nm, functionalized with thiol- or biotin-terminated oligonucleotides (AuNPsSdT or AuNPsBdT). Our study reveals that 103 nm AuNPsSdT are the best option to improve the assay performance due to their high colloidal stability, a release efficiency exceeding 90%, and a sensor response enhancement factor exceeding 105. We demonstrate that in conjunction with 103 nm AuNPsSdT, the AuNP release assay can detect hsa-miR-451a at levels down to 40 aM and quantify hsa-miR-451a physiological levels in human blood plasma. Moreover, we use the assay to demonstrate a significant down-regulation of hsa-miR-451a in blood plasma of MDS patients compared to healthy individuals, suggesting the potential relevance of hsa-miR-451a as a prospective MDS biomarker.
Collapse